Definium Therapeutics to present at TD Cowen Novel Mechanisms in Neuropsychiatry Summit
PUBT · 1d ago
Share
Listen to the news
- Definium Therapeutics schedules a virtual fireside chat on Tuesday, Sept. 1, 2026 at 1:00 p.m. ET.
- Discussion to cover Phase 3 Voyage topline results for DT120 ODT in generalized anxiety disorder.
- Management also slated to present at TD Cowen’s Novel Mechanisms in Neuropsychiatry Summit on Wednesday, Sept. 23, 2026 at 9:30 a.m. ET.
- Company plans to attend the 2026 Leerink Partners Biopharma Summit in Healdsburg, California from Sept. 23-25, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608260701BIZWIRE_USPR_____20260826_BW612661) on August 26, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending